TOKYO, Dec. 17, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets. By combining Talus Bio's assay technologies for screening for TF and PPI inhibitors in native cellular environment with PRISM's chemistry designed to target protein-protein interactions, companies are in a unique position to disc

Evoke Stockholders Received $11.00 Per Share in Cash SOLANA BEACH, Calif., and VERO BEACH, Fla., Dec. 17, 2025 /PRNewswire/ -- Evoke Pharma, Inc. (formerlyNASDAQ: EVOK) ("Evoke") and QOL Medical, LLC ("QOL Medical") today announced that the tender offer (the "Offer") by QOL-EOS Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of QOL Medical (the "Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the "Shares"), of Evo

AUSTIN, Texas and TOKYO, Dec. 17, 2025 /PRNewswire/ -- According to DataM Intelligence, the global Disease-Modifying Therapies (DMTs) Market was valued at USD 65.32 billion in 2024 and is projected to reach USD 112.64 billion by 2033, expanding at a CAGR of 6.2% during the forecast period 2025–2033. This steady yet structurally important growth reflects a fundamental transformation in chronic disease management. Healthcare systems are increasingly shifting from symptom-focused treatment towa

Lotus Neuro builds on Insightec's groundbreaking focused ultrasound platform to accelerate next-generation brain therapies globally, with funding from Nexus NeuroTech Ventures. MIAMI and HAIFA, Israel, Dec. 17, 2025 /PRNewswire/ -- Insightec, a global healthcare innovator pioneering the use of focused ultrasound to transform patient care, today announced the spin-out and launch of Lotus Neuro, a new clinical stage biotechnology company advancing the next generation of brain‑targeted therapeutics

PHILADELPHIA, Dec. 17, 2025 /PRNewswire/ -- In 2025, MOBILion Systems achieved a decisive technical milestone through proof-of-concept demonstration that high-resolution ion mobility (HRIM), operated in MOBILion's unique PAMAF mode, fundamentally reshapes mass-spectrometry-based proteomics. This work empirically demonstrates what the field has theorized for more than two decades and does so in a way existing technologies are unable to match. More than 25 years ago, leading experts identified a f

With federal regulators intensifying scrutiny of PBM practices and employers facing mounting ERISA and CAA-2021 fiduciary exposure, the need for a fiduciary compliant, conflict-free pharmacy benefits model has never been more urgent. US-Rx Care— the nation's first fiduciary PBM—delivers a legally aligned, clinically rigorous, and financially transparent alternative that consistently reduces plan and member costs by 30–50%. HOLLYWOOD, Fla., Dec. 17, 2025 /PRNewswire/ -- A wave of federal scrutiny

ASPIRE pivotal IDE study results demonstrated PearlMatrix achieved superior clinical success and superior time-to-fusion at 24 months compared to local autograft. The rigor of the ASPIRE study reflects unmatched clinical design and results including: - More than twice as many patients fused at 6 months - Approximately 60% high-risk patients - As safe as local autograft WESTMINSTER, Colo., Dec. 17, 2025 /PRNewswire/ -- Cerapedics Inc., a global, commercial-stage orthopedics company dedicated to

SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has performed an in silico analysis of the Co-Primers® used in its Logix Smart® ABC test* for the detection of influenza A, influenza B and COVID-19. The analysis showed a high homology against 3,900 influenza sequences, confirming comparable reacti

Study demonstrated clear target engagement at both tested doses Potential for THRV-1268 to address prolonged QTcF in cardiometabolic diseases Phase 2a ASPIRE-HF study to commence enrollment in 2026 MONTREAL, Dec. 17, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias and cardiometabolic diseases, today announced encouraging results from a recently comple

Sets new benchmark in cold chain logistics with real-time monitoring, sustainable design, and highly trained Life Sciences specialists. Strengthens DHL's network of 112 Air GxP and 22 IATA CEIV Pharma-certified stations worldwide, reinforcing its leadership in compliant and sustainable healthcare logistics. LOS ANGELES, Dec. 17, 2025 /PRNewswire/ -- DHL Global Forwarding, the air and ocean freight specialist of Deutsche Post DHL Group, is excited to announce the expansion of its cold storage fac